SI

Sintx Technologies, Inc.

SINTHealthcareNASDAQ

Medical Devices · Last scanned Jul 22, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$729,000
-41.5% YoY
Net Income
-$10.4M
+6.0% YoY
EBITDA
-$9.7M
-0.4% YoY
Free Cash Flow
-$3.7M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 RSI OversoldRSI 22.7, below 30, stock may be oversold
Jul 14 RSI OversoldRSI 20.6, below 30, stock may be oversold
About Sintx Technologies, Inc.

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and. The $10.0M market capitalization puts SINT squarely in micro-cap range for its industry. The company offers monolithic solid silicon nitride; solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyether ether ketone, and Polyether Ether Ketone (PEE).

Where SINT stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, SINT finished 43.68% below its 150-day moving average ($2.77) and 48.00% below its 200-day moving average ($3.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is SINT overbought or oversold?

At the July 15, 2026 close, SINT's RSI(14) was 22.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$10.0M
Fwd P/E-1.10
EPS$-5.55
Beta0.63
52W Change-39.7%
ROE-311.4%
Analysis

On the balance sheet, SINT has $1.9M in cash with $3.3M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$3.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -311.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $601K (2022) to $729K (2025), reflecting a 21% increase over the period.

With a beta below 0.7, Sintx Technologies, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sintx Technologies, Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
SINT: Sintx Technologies, Inc. Technical Analysis (200-Day MA, RSI, MACD) | Scanance